Remimazolam Delirium Meta-Analysis Combined Trial and Cohort Evidence

Combining randomized and observational studies requires attention to what each design can establish.

What the supplied source reports

This synthesis included eleven studies with 2,188 patients. It reported no statistically significant reduction in postoperative delirium with remimazolam: the odds ratio was 0.79, with a 95% confidence interval of 0.53–1.17. Lower pooled rates of hypotension and bradycardia were reported, while several other outcomes remained inconclusive.

Limits of the evidence

The eligibility criteria admitted both randomized trials and cohorts. Those designs differ in susceptibility to treatment-selection bias. Delirium results also showed moderate statistical heterogeneity. A confidence interval crossing one does not prove that the drugs have identical cognitive effects.

Implications for expert analysis

For testimony, distinguish the delirium endpoint from cardiovascular events and identify which designs contributed to each estimate. A circulation advantage cannot substitute for a demonstrated cognitive benefit. The defensible conclusion is that this synthesis did not establish delirium prevention, while reporting a separate hemodynamic signal.

Source and related reading

Source: Publication PMC12486766, read from the supplied PDF. Applications to expert analysis are interpretation.